Last reviewed · How we verify

Neuropathic diabetic ulcer - foot — Treatment Landscape & Competitive Intelligence

Neuropathic diabetic ulcer - foot (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neuropathic diabetic ulcer - foot, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Regranex BECAPLERMIN Omj Pharmaceuticals Human Platelet-derived Growth Factor Platelet-derived growth factor receptor 1997-01-01
Regranex Regranex Solsys Medical LLC Platelet-derived growth factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Omj Pharmaceuticals · 1 drug in Neuropathic diabetic ulcer - foot
  2. Solsys Medical LLC · 1 drug in Neuropathic diabetic ulcer - foot

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neuropathic diabetic ulcer - foot:

Cite this brief

Drug Landscape (2026). Neuropathic diabetic ulcer - foot — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuropathic-diabetic-ulcer-foot. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing